Literature DB >> 17854599

Evidence against a role for NADPH oxidase modulating hepatic vascular tone in cirrhosis.

Jorge Gracia-Sancho1, Bàrbara Laviña, Aina Rodríguez-Vilarrupla, Ralf P Brandes, Mercedes Fernández, Jaume Bosch, Joan-Carles García-Pagán.   

Abstract

BACKGROUND & AIMS: Increased hepatic vascular resistance in cirrhosis is in part due to reduced nitric oxide (NO) bioavailability. This is related to insufficient NO synthesis from endothelial nitric oxide synthase and to enhanced NO scavenging by superoxide radicals (O(2)(-)). Nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase is an important source of O(2)(-) that increases vascular tone in different cardiovascular disorders. Thus, our aims were to study the molecular and biochemical state of NADPH-oxidase in cirrhotic livers and to investigate its possible role in modulating hepatic vascular tone in cirrhosis.
METHODS: NADPH-oxidase expression and enzymatic activity were determined in control (n = 8) and CCl(4)-cirrhotic (n = 8) rat livers. Additional control (n = 6) and CCl(4)-cirrhotic (n = 10) rats were treated with apocynin (a selective NADPH-oxidase inhibitor) or its vehicle. Mean arterial pressure, portal pressure, and superior mesenteric arterial blood flow were measured in vivo. Moreover, hepatic endothelial function was evaluated in isolated and perfused rat livers by dose-response curves to acetylcholine. In addition, in 6 control and 6 cirrhotic human livers NADPH-oxidase activity and expression were evaluated.
RESULTS: Rat cirrhotic livers had no increased NADPH-oxidase protein expression or activity in relation to control livers. NADPH-oxidase inhibition did not modify splanchnic or systemic hemodynamics in control or cirrhotic rats and did not improve the impaired endothelial-dependent vasodilatory response to acetylcholine of cirrhotic livers. Human cirrhotic livers also did not exhibit increased NADPH-oxidase expression or activity.
CONCLUSIONS: Our study shows that NADPH-oxidase activity is decreased in the cirrhotic livers and therefore cannot explain increased hepatic O(2)(-), endothelial dysfunction, and increased vascular tone in cirrhotic livers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17854599     DOI: 10.1053/j.gastro.2007.06.021

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

Review 1.  New cellular and molecular targets for the treatment of portal hypertension.

Authors:  Jordi Gracia-Sancho; Raquel Maeso-Díaz; Anabel Fernández-Iglesias; María Navarro-Zornoza; Jaime Bosch
Journal:  Hepatol Int       Date:  2015-03-05       Impact factor: 6.047

Review 2.  Role of liver sinusoidal endothelial cells in liver diseases.

Authors:  Jordi Gracia-Sancho; Esther Caparrós; Anabel Fernández-Iglesias; Rubén Francés
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-15       Impact factor: 46.802

3.  Thyroid hormone-induced cytosol-to-nuclear translocation of rat liver Nrf2 is dependent on Kupffer cell functioning.

Authors:  Luis A Videla; Pamela Cornejo; Pamela Romanque; Catherine Santibáñez; Iván Castillo; Romina Vargas
Journal:  ScientificWorldJournal       Date:  2011-12-20

4.  Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats.

Authors:  Eugenio Rosado; Aina Rodríguez-Vilarrupla; Jorge Gracia-Sancho; Montserrat Monclús; Jaume Bosch; Joan-Carles García-Pagán
Journal:  J Cell Mol Med       Date:  2012-10       Impact factor: 5.310

5.  Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy.

Authors:  Diana Hide; Martí Ortega-Ribera; Juan-Carlos Garcia-Pagan; Carmen Peralta; Jaime Bosch; Jordi Gracia-Sancho
Journal:  Sci Rep       Date:  2016-02-24       Impact factor: 4.379

6.  Platelets prime hematopoietic and vascular niche to drive angiocrine-mediated liver regeneration.

Authors:  Koji Shido; Deebly Chavez; Zhongwei Cao; Jane Ko; Shahin Rafii; Bi-Sen Ding
Journal:  Signal Transduct Target Ther       Date:  2017-02-17

7.  Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies.

Authors:  Fernanda Cristina de Mesquita; Sergi Guixé-Muntet; Anabel Fernández-Iglesias; Raquel Maeso-Díaz; Sergi Vila; Diana Hide; Martí Ortega-Ribera; José Luís Rosa; Juan Carlos García-Pagán; Jaime Bosch; Jarbas Rodrigues de Oliveira; Jordi Gracia-Sancho
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

8.  Novel treatment options for portal hypertension.

Authors:  Philipp Schwabl; Wim Laleman
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-04-18

9.  Effects of aging on liver microcirculatory function and sinusoidal phenotype.

Authors:  Raquel Maeso-Díaz; Martí Ortega-Ribera; Anabel Fernández-Iglesias; Diana Hide; Leticia Muñoz; Amelia J Hessheimer; Sergi Vila; Rubén Francés; Constantino Fondevila; Agustín Albillos; Carmen Peralta; Jaime Bosch; Frank Tacke; Victoria C Cogger; Jordi Gracia-Sancho
Journal:  Aging Cell       Date:  2018-09-08       Impact factor: 9.304

10.  Salvianolic Acid B reducing portal hypertension depends on macrophages in isolated portal perfused rat livers with chronic hepatitis.

Authors:  Xin Zhao; Hongmei Jia; Shijun Yang; Yuetao Liu; Bo Deng; Xueyan Xu; Tao Zhang; Hang Zhou; Chengzhe Zu; He Yin; Ting Li; Yijun Song; Yueqi Wang; Pengtao Li; Zhongmei Zou; Dayong Cai
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-16       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.